Effects of atomoxetine on cognitive functions in normal subjects using fMRI

Effects of atomoxetine on cognitive functions in normal subjects using fMRI - Effects of atomoxetine on cognitive functions in normal subjects using fMRI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012947

Enrollment

Registered

2014-01-24

Start date

2012-12-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

1day 1 time atomoxetine 40 mg Washout duration 1 week 1day 1 time placebo 1day 1 time placebo Washout duration 1 week 1day 1 time atomoxetine 40 mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects with no history of psychiatric disorders. Subjects who have the ability to provide informed consent and adhere to the protocol.

Exclusion criteria

Exclusion criteria: Subjects with drug allergy. Subjects with cardiovascular disorder, glaucoma, liver and renal dysfunction, urination difficulty. Subjects with history of pheochromocytoma, convulsive seizure, hypertension, cerebrovascular disorder, orthostatic hypotension. Subjects taking any drug within 1 week. Subjects with contraindications to MRI. Subjects who are judged as not suitable for participation in this study.

Design outcomes

Primary

Measure	Time frame
Comparison of BOLD signal changes measured by fMRI between placebo and atomoxetine conditions.	—

Countries

Japan

Contacts

Public ContactYumiko Ikeda

Nippon Medical School Department of Pharmacology

y-ikeda@nms.ac.jp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026